Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 16, 2025 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000050 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,200 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 16, 2025 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,200 | $61.24 | $134,728.00 |
DisclosureSEC source: 0001061983-25-000050 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,552 Read SEC document |
| December 16, 2025 Filed Dec 16, 2025 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,200 | $10.60 | $23,320.00 |
DisclosureSEC source: 0001061983-25-000050 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,058 | $65.02 | $133,811.16 |
DisclosureSEC source: 0001061983-25-000044 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,552 F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted on March 14, 2024 and earned December 2, 2024. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:10 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000041 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:10 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,200 | $63.89 | $140,558.00 |
DisclosureSEC source: 0001061983-25-000041 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:10 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,200 | $10.60 | $23,320.00 |
DisclosureSEC source: 0001061983-25-000041 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000037 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 2,200 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,200 | $66.45 | $146,190.00 |
DisclosureSEC source: 0001061983-25-000037 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,200 | $10.60 | $23,320.00 |
DisclosureSEC source: 0001061983-25-000037 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,295 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000029 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 2,295 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,295 | $59.55 | $136,667.25 |
DisclosureSEC source: 0001061983-25-000029 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,295 | $10.60 | $24,327.00 |
DisclosureSEC source: 0001061983-25-000029 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2025 Filed Oct 21, 2025 22:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,105 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000025 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 2,105 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2025 Filed Oct 21, 2025 22:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,105 | $58.22 | $122,553.10 |
DisclosureSEC source: 0001061983-25-000025 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| October 21, 2025 Filed Oct 21, 2025 22:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,105 | $10.60 | $22,313.00 |
DisclosureSEC source: 0001061983-25-000025 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000009 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $60.56 | $121,120.00 |
DisclosureSEC source: 0001061983-25-000009 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001061983-25-000009 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2025 Filed Sep 23, 2025 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000005 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2025 Filed Sep 23, 2025 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $49.28 | $98,560.00 |
DisclosureSEC source: 0001061983-25-000005 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| September 23, 2025 Filed Sep 23, 2025 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001061983-25-000005 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-021253 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $51.29 | $102,580.00 |
DisclosureSEC source: 0001127602-25-021253 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 20:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-021253 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-020711 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $38.31 | $76,620.00 |
DisclosureSEC source: 0001127602-25-020711 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-020711 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-020109 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $36.34 | $72,680.00 |
DisclosureSEC source: 0001127602-25-020109 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-020109 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 15:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-019506 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 15:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $37.47 | $74,940.00 |
DisclosureSEC source: 0001127602-25-019506 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 15:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-019506 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2025 Filed Jul 8, 2025 20:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-019021 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2025 Filed Jul 8, 2025 20:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $33.76 | $67,520.00 |
DisclosureSEC source: 0001127602-25-019021 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| July 08, 2025 Filed Jul 8, 2025 20:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-019021 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jul 18, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026407 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-017640 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $32.91 | $65,820.00 |
DisclosureSEC source: 0001127602-25-017640 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-017640 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-016470 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $31.88 | $63,760.00 |
DisclosureSEC source: 0001127602-25-016470 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-016470 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2025 Filed May 20, 2025 20:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-015023 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2025 Filed May 20, 2025 20:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $31.98 | $63,960.00 |
DisclosureSEC source: 0001127602-25-015023 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,255 Read SEC document |
| May 20, 2025 Filed May 20, 2025 20:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-015023 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2025 Filed May 6, 2025 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-013482 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2025 Filed May 6, 2025 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $35.01 | $70,020.00 |
DisclosureSEC source: 0001127602-25-013482 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,255 Read SEC document |
| May 06, 2025 Filed May 6, 2025 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-013482 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.